Invented by Tomohiro Tanaka, Noriyuki Iwabuchi, Yohei Sato, Kanetada Shimizu, Toshitaka Odamaki, Morinaga Milk Industry Co Ltd
The Morinaga Milk Industry Co Ltd invention works as followsA method of prophylaxis and treatment of a disease involves administering an effective amount of an agent that has cells of Lactobacillus Paracasei MCC1849 (NITEBP-01633) to the subject who is in need of such treatment or prophylaxis. It could be an inflammatory condition, ulcer, food allergy, bronchial asthma or opportunistic disease.
Background for Lactic Acid Bacterium, Drug, Food or Drink, and Feed which Contain the Lactic Acid bacterium.
Object to be Achieved Through the Invention
The present invention aims to provide a lactic acids bacterium that can be used for prophylaxis or defense against different infections. This i.e., a lactic acids bacterium with high IL-12 production-promoting and immunostimulation actions, which are preferably not easily diminished in humans, etc.
Means to Achieve the Object
In order achieve the aforementioned objects, the inventors searched diligently for such target lactic acids bacteria and discovered a novel strain Lactobacillus Paracasei with a high IL-12 production-promoting effect. They thus achieved the invention.
That’s because the present invention provides the Lactobacillus Paracasei MCC1849 strain (NITE BP-01633).
The invention also includes a drug that contains the strain.
In a preferred embodiment, the drug is intended for immunostimulation.
In a preferred embodiment, the drug is for anti-virus.
In a preferred embodiment, the drug is for the anti-influenza virus in the aforementioned drug.
The invention also provides food and drinks that contain the strain.
The present invention also provides a feed that contains the strain.
The invention also contains an IL-12 production-promoting drug that contains the strain.
In a preferred embodiment, the IL-12 production-promoting agents is in the form a food or drink.
Hereafter, we will explain in detail the present invention.
The present invention is related to the Lactobacillus Paracasei MCC1849 strain (NITE BP-01633), which is a novel strain a lactic acid bacteriaium belonging to Lactobacillus Paracasei. This strain will be referred to as either the?lactic acid bacteria of the invention? or the??strain of this invention? or simply the MCC1849 strain.
The present invention uses human feces to isolate the lactic acid bacteriaium. This example will describe the bacteriological characteristics and details of this strain. This strain was filed on Jun. June 6, 2013, at the NITE Patent Microorganisms Depository, National Institute of Technology and Evaluation (#122), Kazusakamatari. Kisarazushi. Chiba, 292-0818, Japan). The accession number of NITE BP-01633 was given to the deposit.
DEPOSIT OF MICROORGANISM
The lactic acid bacteria of the invention is not limited by the deposited strain. It may also be substantially equivalent to that strain. A strain belonging to Lactobacillus Paracasei is a strain that exhibits IL-12 production-promoting activity at a level comparable with that exhibited in the deposited strain. It should also preferably show a reduction of the IL-12-promoting effect at a low level comparable that exhibited in the deposited strain after treatment with a cell-wall-digesting enzyme (RNase). The substantially equivalent strain also shows homology in the nucleotide sequences of the 16SRNA genes of the deposited strain. Preferably, it has the same bacteriological characteristics and biochemical properties as the deposited strain. The lactic acid bacteria of the invention can also be a strain that was bred from the deposited plant or a strain that is substantially identical to it by mutation treatment, gene replication, selection of a naturally mutant strain, or any other means, provided the effect of this invention is not diminished.
The MCC1849 strain is more IL-12 (interleukin-12-producing) than other known lactic acids bacteria. The IL-12-producing activity of lactic acids bacteria can be markedly decreased by treatment with a cell-wall-digesting enzyme like N-acetylmuramidase or RNase. However, the MCC1849 strain has a lower IL-12 production-promoting ability even after treatment with a cell-wall-digesting protein or RNase. You can measure the IL-12 production-promoting activities using the method described in “Example”.Click here to view the patent on Google Patents.